Return to search

Substrate-based inhibitors of peptidylglycine á-amidating monooxygenase (PAM) as anti-proliferative drugs for cancer [electronic resource] / by Geoffrey H Chew.

Title from PDF of title page. / Document formatted into pages; contains 48 pages. / Thesis (M.S.)--University of South Florida, 2003. / Includes bibliographical references. / Text (Electronic thesis) in PDF format. / ABSTRACT: C-Terminal glycine-extended prohormones are enzymatically converted to á-amidated peptides, by peptidylglycine á-amidating monooxygenase (PAM). PAM is a bifunctional enzyme with two catalytic domains: peptidylglycine á -hydroxylating monooxygenase (PHM) and peptidylglycine peptidylglycineaminoglycolate lyase (PAL). PAM has a significant role in the proliferation of androgen-independent prostate cancer. Thus, the inhibition of PAM could halt cancer growth. Hippurate and hippurate analogs were used as lead compounds for developing inhibitors for PAM. The hippurate analogs exhibiting the highest affinity to PAM (lowest inhibition constant) did inhibit the growth of human androgen-independent prostate cancer DU 145 cells. / System requirements: World Wide Web browser and PDF reader. / Mode of access: World Wide Web.

Identiferoai:union.ndltd.org:USF/oai:palmm.fcla.edu:AJM5913SEB
Date January 2003
CreatorsChew, Geoffrey H.
PublisherUniversity of South Florida
Source SetsUniversity of South Flordia
Detected LanguageEnglish

Page generated in 0.002 seconds